Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Made to Feel Like Less of a Woman: The Experience of Stigma for Mothers Who Do Not Breastfeed.

Bresnahan M, Zhuang J, Goldbort J, Bogdan-Lovis E, Park SY, Hitt R.

Breastfeed Med. 2020 Jan;15(1):35-40. doi: 10.1089/bfm.2019.0171. Epub 2019 Dec 20.

PMID:
31859523
2.

Establishment of Chronic Typhoid Infection in a Mouse Carriage Model Involves a Type 2 Immune Shift and T and B Cell Recruitment to the Gallbladder.

González JF, Kurtz J, Bauer DL, Hitt R, Fitch J, Wetzel A, La Perle K, White P, McLachlan J, Gunn JS.

mBio. 2019 Oct 1;10(5). pii: e02262-19. doi: 10.1128/mBio.02262-19.

3.

Too Old to Be Breastfed? Examination of Pre-Healthcare Professionals' Beliefs About, and Emotional and Behavioral Responses toward Extended Breastfeeding.

Zhuang J, Hitt R, Goldbort J, Gonzalez M, Rodriguez A.

Health Commun. 2019 Mar 1:1-9. doi: 10.1080/10410236.2019.1584739. [Epub ahead of print]

PMID:
30822154
4.

Hearing loss and quality of life.

Punch JL, Hitt R, Smith SW.

J Commun Disord. 2019 Mar - Apr;78:33-45. doi: 10.1016/j.jcomdis.2019.01.001. Epub 2019 Jan 6.

PMID:
30639959
5.

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.

Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB.

Ann Oncol. 2018 May 1;29(5):1130-1140. doi: 10.1093/annonc/mdy102.

6.

Media Presentation of Breastfeeding Beliefs in Newspapers.

Hitt R, Zhuang J, Anderson J.

Health Commun. 2018 Oct;33(10):1293-1301. doi: 10.1080/10410236.2017.1351275. Epub 2017 Aug 18.

PMID:
28820632
7.

Risk Belief and Attitude Formation From Translated Scientific Messages About PFOA, an Environmental Risk Associated With Breast Cancer.

Smith SW, Hitt R, Russell J, Nazione S, Silk K, Atkin CK, Keating D.

Health Commun. 2017 Mar;32(3):279-287. doi: 10.1080/10410236.2016.1138350. Epub 2016 May 24.

PMID:
27219106
8.

Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).

Echarri MJ, Lopez-Martin A, Hitt R.

Cancers (Basel). 2016 Feb 26;8(3). pii: E27. doi: 10.3390/cancers8030027. Review.

9.

An Effort to Increase Organ Donor Registration Through Intergroup Competition and Electronic Word of Mouth.

Smith SW, Hitt R, Park HS, Walther J, Liang YJ, Hsieh G.

J Health Commun. 2016;21(3):376-86. doi: 10.1080/10810730.2015.1095815. Epub 2016 Jan 6.

PMID:
26735448
10.

Scientific Message Translation and the Heuristic Systematic Model: Insights for Designing Educational Messages About Progesterone and Breast Cancer Risks.

Hitt R, Perrault E, Smith S, Keating DM, Nazione S, Silk K, Russell J.

J Cancer Educ. 2016 Jun;31(2):389-96. doi: 10.1007/s13187-015-0835-y.

11.

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.

Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE.

Ann Oncol. 2014 Sep;25(9):1813-20. doi: 10.1093/annonc/mdu216. Epub 2014 Jun 13.

12.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2014 Jan;25(1):216-25. doi: 10.1093/annonc/mdt461. Epub 2013 Nov 19.

13.

Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.

Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group.

J Clin Oncol. 2013 Aug 10;31(23):2854-60. doi: 10.1200/JCO.2012.47.7802. Epub 2013 Jul 8.

PMID:
23835714
14.

The effects of heuristic cues, motivation, and ability on systematic processing of information about breast cancer environmental factors.

Smith SW, Hitt R, Nazione S, Russell J, Silk K, Atkin CK.

J Health Commun. 2013;18(7):845-65. doi: 10.1080/10810730.2013.768722. Epub 2013 May 14.

PMID:
23672206
15.

Comparison of communication and personal characteristics of living kidney donors and a matched quota sample.

Smith SW, Hitt R, Nazione S, Lauckner C, Park HS, Sung R, Leichtman A.

Clin Transplant. 2013 Jan-Feb;27(1):104-12. doi: 10.1111/ctr.12026. Epub 2012 Oct 16.

16.

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.

Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL.

Cancer. 2012 Oct 1;118(19):4694-705. doi: 10.1002/cncr.27449. Epub 2012 Mar 20.

17.

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2012 Apr;23(4):1016-22. doi: 10.1093/annonc/mdr367. Epub 2011 Aug 23.

18.

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.

Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, Temam S, Cupissol D, De Raucourt D, Maroudias N, Nutting CM, Compton N, Midwinter D, Downie L, Biswas-Baldwin N, El-Hariry I, Harrington KJ.

Br J Cancer. 2011 Aug 23;105(5):618-27. doi: 10.1038/bjc.2011.237. Epub 2011 Aug 9.

19.

Update on the diagnosis of cancer of unknown primary (CUP) origin.

Ariza A, Balañá C, Concha Á, Hitt R, Homet B, Matilla A, Alba E.

Clin Transl Oncol. 2011 Jul;13(7):434-41. doi: 10.1007/s12094-011-0679-9.

PMID:
21775269
20.

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB.

Ann Oncol. 2011 May;22(5):1078-87. doi: 10.1093/annonc/mdq588. Epub 2010 Nov 3.

21.

Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival.

Homet B, Hitt R, Ghanem I, Cortés-Funes H.

Clin Transl Oncol. 2010 Aug;12(8):574-5. doi: 10.1007/s12094-010-0556-y.

PMID:
20709655
22.

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Homet Moreno B, Garralda Cabanas E, Hitt R.

Clin Transl Oncol. 2010 Jul;12(7):468-72. doi: 10.1007/s12094-010-0539-z. Review.

PMID:
20615823
23.

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.

Martinez-Trufero J, Isla D, Adansa JC, Irigoyen A, Hitt R, Gil-Arnaiz I, Lambea J, Lecumberri MJ, Cruz JJ.

Br J Cancer. 2010 Jun 8;102(12):1687-91. doi: 10.1038/sj.bjc.6605697. Epub 2010 May 18.

24.

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB.

Ann Oncol. 2010 Oct;21(10):1967-73. doi: 10.1093/annonc/mdq077. Epub 2010 Mar 24.

25.

A new paradigm for MAPK: structural interactions of hERK1 with mitochondria in HeLa cells.

Galli S, Jahn O, Hitt R, Hesse D, Opitz L, Plessmann U, Urlaub H, Poderoso JJ, Jares-Erijman EA, Jovin TM.

PLoS One. 2009 Oct 22;4(10):e7541. doi: 10.1371/journal.pone.0007541.

26.

Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease.

Montag J, Hitt R, Opitz L, Schulz-Schaeffer WJ, Hunsmann G, Motzkus D.

Mol Neurodegener. 2009 Aug 27;4:36. doi: 10.1186/1750-1326-4-36.

27.

Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma.

González-Billalabeitia E, Hitt R, Fernández J, Conde E, Martínez-Tello F, Enríquez de Salamanca R, Cortés-Funes H.

Clin Transl Oncol. 2009 Jul;11(7):479-83.

PMID:
19574207
28.

Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of mycophenolic acid reveals effects independent of inosine monophosphate dehydrogenase inhibition.

Petrova DT, Heller T, Hitt R, Wieland E, Oellerich M, Armstrong VW, Shipkova M.

Ther Drug Monit. 2009 Feb;31(1):31-41. doi: 10.1097/FTD.0b013e318192693e.

PMID:
19065122
29.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R.

N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.

30.

Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions.

Lee JM, Georgian-Smith D, Gazelle GS, Halpern EF, Rafferty EA, Moore RH, Yeh ED, D'Alessandro HA, Hitt RA, Kopans DB.

Radiology. 2008 Aug;248(2):398-405. doi: 10.1148/radiol.2482071635. Epub 2008 Jun 6.

PMID:
18539887
31.

Coexistence of two rare sarcomas: primary leiomyosarcoma of bone and epithelioid hemangioendothelioma of the liver.

Gonzalez-Billalabeitia E, Quintela-Fandino M, Alemany I, López-Alonso G, Ruiz-Ollero A, Martinez-Tello F, Hitt R.

Sarcoma. 2008;2008:416085. doi: 10.1155/2008/416085.

32.

Case records of the Massachusetts General Hospital. Case 4-2008. A 33-year-old pregnant woman with swelling of the left breast and shortness of breath.

Shulman LN, Hitt RA, Ferry JA.

N Engl J Med. 2008 Jan 31;358(5):513-23. doi: 10.1056/NEJMcpc0707921. No abstract available.

PMID:
18234756
33.

CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma--a pilot study.

Fialka F, Gruber RM, Hitt R, Opitz L, Brunner E, Schliephake H, Kramer FJ.

Oral Oncol. 2008 Oct;44(10):941-8. doi: 10.1016/j.oraloncology.2007.10.011. Epub 2008 Jan 29.

PMID:
18234543
34.
35.

Primary pulmonary artery sarcoma: report of three cases and review of the literature.

Manso L, Alvarez E, Quintela M, Cortes-Funes H, Hitt R.

Clin Lung Cancer. 2007 Jan;8(4):277-81.

PMID:
17311694
36.

Molecular biology in head and neck cancer.

Hitt R, Echarri MJ.

Clin Transl Oncol. 2006 Nov;8(11):776-9. Review.

PMID:
17134964
37.

Induction chemotherapy in head and neck cancer.

Hitt R.

Ann Oncol. 2006 Sep;17 Suppl 10:x42-4. Review. No abstract available.

38.

Cetuximab in squamous cell carcinoma of the head and neck.

Hitt R, Martín P, Hidalgo M.

Future Oncol. 2006 Aug;2(4):449-57. Review.

PMID:
16922611
39.

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.

J Clin Oncol. 2006 Sep 10;24(26):4333-9. Epub 2006 Aug 8.

PMID:
16896002
40.

Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.

Quintela-Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortés-Funes H.

J Clin Oncol. 2006 Aug 1;24(22):3611-8.

PMID:
16877728
41.

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A.

J Clin Oncol. 2006 Jun 20;24(18):2866-72. Epub 2006 May 22.

PMID:
16717293
42.

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Hitt R, Amador ML, Quintela-Fandino M, Jimeno A, del Val O, Hernando S, Cortes-Funes H.

Cancer. 2006 Jan 1;106(1):106-11.

43.

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.

J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. Erratum in: J Clin Oncol. 2006 Feb 20;24(6):1015.

PMID:
16275937
44.

beta-Catenin, Nf-kappaB and FAS protein expression are independent events in head and neck cancer: study of their association with clinical parameters.

Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, Sanchez JJ, Sanchez-Verde L, Alameda F, Ballestin C, Sanchez-Cespedes M.

Cancer Lett. 2005 Dec 8;230(1):141-8.

PMID:
16253770
45.

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.

León X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF, Amellal N, Bessa EH, Bourhis J.

Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24.

PMID:
16149284
46.

Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A.

J Clin Oncol. 2005 Aug 20;23(24):5568-77. Epub 2005 Jul 11.

PMID:
16009950
47.

A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center.

Lally MA, MacNevin R, Sergie Z, Hitt R, DiSpigno M, Cenedella C, Stein MD.

AIDS Patient Care STDS. 2005 May;19(5):298-305.

48.

Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.

Hitt R, Ciruelos E, Amador ML, Benito A, Sanchez JJ, Ballestin C, Cortes-Funes H.

Eur J Cancer. 2005 Feb;41(3):453-60.

PMID:
15691646
49.

Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.

Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, Sanchez JJ, Ballestin C, Diez A, Sanchez-Verde L, Alameda F, Sanchez-Cespedes M.

Clin Cancer Res. 2004 Dec 15;10(24):8486-92.

50.

Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma.

Jimeno A, Hitt R, Quintela-Fandino M, Cortés-Funes H.

Anticancer Drugs. 2005 Jan;16(1):53-7.

PMID:
15613904

Supplemental Content

Support Center